Related Experiment Videos
Matrix metalloproteinases
L L Johnson1, R Dyer, D J Hupe
1Department of Biochemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA. Linda.Johnson@wl.com
Current Opinion in Chemical Biology
|September 16, 1998
Summary
Matrix metalloproteinases (MMPs) are key enzymes in tissue remodeling. Recent advances in knockout models and selective inhibitors offer new ways to study and treat MMP-related diseases like cancer and arthritis.
Area of Science:
- Biochemistry
- Molecular Biology
- Pathology
Background:
- Matrix metalloproteinases (MMPs) are crucial peptidases regulating extracellular matrix degradation during tissue remodeling.
- Dysregulated MMP activity is linked to diseases such as cancer and arthritis.
- Emerging research connects MMPs to an expanding range of pathologies.
Purpose of the Study:
- To highlight recent advancements in understanding matrix metalloproteinases.
- To discuss new tools for assessing MMP activity in disease models.
- To review the progress of MMP inhibitors in clinical trials.
Main Methods:
- Development of new transgenic models for matrix metalloproteinase knockouts.
- Clinical trials evaluating selective MMP inhibitors with improved pharmacokinetic profiles.
Main Results:
- Transgenic models enable direct assessment of specific MMP activity in disease contexts.
- Selective MMP inhibitors are progressing through clinical trials, allowing safety and efficacy evaluations.
Conclusions:
- New research tools and therapeutic strategies are advancing the study of matrix metalloproteinases.
- Targeting MMPs holds promise for treating a growing list of associated diseases.